Pfizer (NYSE:PFE) Trading 1.4% Higher – Should You Buy?

Pfizer Inc. (NYSE:PFE) traded up 1.4% during mid-day trading on Friday . The company traded as high as $26.21 and last traded at $26.0430. 31,712,250 shares changed hands during trading, a decline of 23% from the average session volume of 41,159,305 shares. The stock had previously closed at $25.69.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a licensing agreement with Chai Discovery that gives it early access to the new Chai-3 AI platform, which could improve its ability to identify and design new drug candidates faster and more efficiently. Article Title
• Positive Sentiment: The company also disclosed ongoing clinical progress in multiple programs, including a Phase 3 infant pneumococcal vaccine trial and new oncology studies in lung and bladder cancer, which supports Pfizer’s pipeline growth narrative. Article Title
• Positive Sentiment: Investors are also focusing on Pfizer’s broader oncology expansion, including combination-trial updates with Astellas and a new PF-08634404 study, which could add future revenue opportunities if results are favorable. Article Title
• Neutral Sentiment: Several articles discussed Pfizer’s recent post-earnings weakness and valuation/dividend comparisons, but these were more commentary than new company-specific developments.

Analysts Set New Price Targets

A number of research analysts have recently commented on PFE shares. Guggenheim increased their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, Morgan Stanley upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.82.

Pfizer Trading Up 1.4%

The business has a 50-day moving average of $26.65 and a 200-day moving average of $26.29. The stock has a market capitalization of $148.43 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PFE. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.